Clinical Trial Update: Treatment With TNF Blockade, Infliximab, in Patients With Myositis [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating infliximab, a TNF blocker, in patients with refractory myositis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myositis

Drugs mentioned

• Infliximab (infliximab)

Snippet

Sponsor: Karolinska Institutet | Conditions: Refractory Myositis | Phase 2, Phase 3 | Status: COMPLETED